We use cookies on our site to track usage and preferences. Learn more

Mogrify introduces EpiMOGRIFY platform to systematically identify epigenetic switches driving cell identity and cell maintenance

  • Date 12 Oct 2020

Mogrify Limited, a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, today announced the introduction of EpiMOGRIFY. The platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance, directed differentiation and cell conversion.

EpiMOGRIFY is an extension of the Company’s proprietary direct cellular conversion technology, MOGRIFY®, and enables the identification of the optimal culture conditions required to maintain cells in chemically defined media. This can be applied in cGMP manufacture and enhances directed differentiation or cell conversion to support the development of scalable off-the-shelf therapies for diseases with a high unmet clinical need.

EpiMOGRIFY combines gene-regulatory information with a model of a cell’s epigenetic landscape and leverages changes in the level of DNA-histone methylation (H3K4me3 modifications). The platform utilizes data from more than 100 human cell/tissue types (available via the ENCODE and Epigenome Roadmap consortia) to accurately define culture conditions that can maintain the cell identity or induce cell conversion.

The EpiMOGRIFY platform, patent and know-how were co-developed and are co-owned by Duke-NUS (Enrico Pettreto, Associate Professor and Owen Rackham, Assistant Professor at Duke-NUS Medical School), Monash University (Jose Polo, Professor at Monash University) and Mogrify. The research underpinning this novel computational approach has recently been published in Cell Systems* (Kamaraj et al., 2020).

Read more

Join an ambitious, supportive community of world-class scientists, engineers and entrepreneurs

Read more